Vectura Receives Bulgarian Marketing Authorisation For Inhaler

Vectura Receives Bulgarian Marketing Authorisation For Inhaler

LONDON (Alliance News) – Vectura Group PLC Tuesday said partner Sandoz has received marketing authorisation from Bulgarian authorities for its new inhaler for patients with respiratory problems.

It has previously been launched in Denmark, and authorised in Germany, Sweden, Hungary and Romania.

“Bulgaria has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of [chronic obstructive pulmonary disease]. The product’s safety, efficacy and equivalence have been proven in multiple clinical trials,” the company said in a statement.

Vectura initially developed the product and created the design of the inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura.


Our Facebook page Comments


We are proud to announce that MEDLINES – Healthcare headlines started its’ very own blog site. Our mission is to bring the very best of the news and newsworthy issues of the medical field, from university news to business and tech info.

One thought on “Vectura Receives Bulgarian Marketing Authorisation For Inhaler

  • March 19, 2014 at 6:20 pm

    Τhanks , I’ve just been searching for info approximately thiѕ topic
    for ages and yyourѕ is the best I’ve came upοn till now.
    But, what іn rеgarгԁs to the сonclusion? Are you
    sure in regardѕ to tɦe supply?

    Fеeеl free tto visit my paցe: great skin care


Leave a Reply